Dublin, July 19, 2024 (GLOBE NEWSWIRE) -- The "Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The global market for Overactive Bladder (OAB) Therapeutics is estimated at US$1.2 Billion in 2023 and is projected to reach US$1.5 Billion by 2030, growing at a CAGR of 2.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. 
The growth in the OAB therapeutics market is driven by several factors. Technological advancements in drug formulation and delivery systems are making treatments more effective and user-friendly, thereby driving demand. The aging global population, which is more susceptible to OAB, is significantly expanding the addressable market. Increased awareness and diagnosis rates of OAB, fueled by educational campaigns and improved diagnostic tools, are leading to higher treatment adoption.
Additionally, the rising prevalence of lifestyle diseases such as diabetes and obesity, which are risk factors for OAB, is contributing to market growth. Pharmaceutical companies are investing heavily in research and development to introduce novel therapeutics with superior efficacy and safety profiles. The integration of digital health solutions is enhancing patient engagement and adherence to treatment regimens.
Furthermore, favorable reimbursement policies and healthcare infrastructure improvements, particularly in emerging markets, are supporting market expansion. The collective impact of these factors is fostering robust growth in the OAB therapeutics market, ensuring better management and improved quality of life for affected individuals.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Anticholinergics Therapy segment, which is expected to reach US$614.7 Million by 2030 with a CAGR of a 3.1%. The Neurostimulation Therapy segment is also set to grow at 2.4% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $332.3 Million in 2023, and China, forecasted to grow at an impressive 4.8% CAGR to reach $290.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Allergan PLC, Astellas Pharma, Inc., Dr. Reddy's Laboratories Ltd., and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 271 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value (USD) in 2023 | $1.2 Billion |
| Forecasted Market Value (USD) by 2030 | $1.5 Billion |
| Compound Annual Growth Rate | 2.8% |
| Regions Covered | Global |
MARKET OVERVIEW
- Influencer Market Insights
- Global Economic Update
- Overactive Bladder (OAB) Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
MARKET TRENDS & DRIVERS
- Aging Global Population Expands Addressable Market Opportunity for OAB Therapeutics
- Innovations in Drug Delivery Systems Propel Growth in OAB Treatment Solutions
- Personalized Medicine Throws the Spotlight on Tailored OAB Therapeutic Approaches
- Advances in Neuromodulation Techniques Strengthen Business Case for Non-Pharmacological Interventions
- Increased Awareness and Diagnosis Rates Drive Adoption of OAB Treatments
- Rising Prevalence of Lifestyle Diseases Generates Demand for OAB Therapeutics
- Integration of Digital Health Technologies Accelerates Demand for Real-Time Symptom Management
- Development of Combination Therapies Enhance Comprehensive Symptom Control
- Improved Diagnostic Tools Enhanced Early Detection and Treatment
- Technological Advancements in Extended-Release Formulations Sustain Growth in OAB Market
- Consumer Preference for Non-Invasive Treatments Expands Market for Alternative Therapies
- Economic Burden of Untreated OAB Fuels Demand for Effective Management Solutions
- Impact of Telemedicine Services on Enhancing Patient Access and Treatment Compliance
FOCUS ON SELECT PLAYERS(Total 34 Featured):
- Allergan PLC
- Astellas Pharma, Inc.
- Dr. Reddy's Laboratories Ltd.
- Eli Lilly and Company
- Endo Pharmaceuticals, Inc.
- Hisamitsu Pharmaceutical Co., Inc.
- Novartis Pharmaceuticals Corporation
- Pfizer, Inc.
- Recordati SpA
- Speciality European Pharma Ltd.
- Sunovion Pharmaceuticals, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/90f0cb
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
